Mesmulogene ancovacivec

{
  "id": "MLC-T-ONC-015104",
  "term": "Mesmulogene ancovacivec",
  "field": "Oncology and biomedicine",
  "definition": "A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with mesmulogene ancovacivec may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells.",
  "abbreviation": "MVA-MUC1-IL2",
  "synonyms": [
    "modified vaccinia ankara encoding human MUC-1 antigen and interleukin-2 suspension",
    "MVA-MUC1-IL2 vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mesmulogene-ancovacivec/"
}